Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.09 USD | -11.31% | -13.03% | -4.61% |
02/05 | Bruker Shares Fall After Q1 Revenue Misses Consensus Views; Lifts Full-Year Guidance | MT |
02/05 | Earnings Flash (BRKR) BRUKER CORPORATION Posts Q1 Revenue $721.7M, vs. Street Est of $729M | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.35 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.67 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.61% | 11.49B | C+ | ||
+7.62% | 219B | B | ||
+6.70% | 183B | B- | ||
+11.94% | 132B | B- | ||
+24.60% | 106B | A- | ||
-2.66% | 62.09B | A- | ||
+4.81% | 50.88B | B+ | ||
+11.55% | 50.8B | B+ | ||
-1.09% | 40.64B | A | ||
+26.82% | 31.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BRKR Stock
- Ratings Bruker Corporation